Matthew Luchini
Stock Analyst at BMO Capital
(1.11)
# 3,493
Out of 4,711 analysts
50
Total ratings
32.14%
Success rate
-8.73%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Luchini
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REPL Replimune Group | Maintains: Outperform | $51 → $30 | $12.49 | +140.19% | 4 | Mar 18, 2022 | |
| JSPR Jasper Therapeutics | Initiates: Outperform | $190 | $21.57 | +780.85% | 1 | Oct 20, 2021 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $89 → $69 | $33.21 | +107.77% | 3 | Sep 10, 2021 | |
| KOD Kodiak Sciences | Maintains: Market Perform | $138 → $104 | $8.65 | +1,102.31% | 3 | May 11, 2021 | |
| CCCC C4 Therapeutics | Initiates: Outperform | $55 | $3.95 | +1,292.41% | 1 | Mar 31, 2021 | |
| ARVN Arvinas | Initiates: Outperform | $101 | $18.48 | +446.54% | 2 | Mar 31, 2021 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $630 | $701.85 | -10.24% | 13 | Jan 25, 2021 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Market Perform | $119 → $124 | $308.44 | -59.80% | 2 | Nov 6, 2020 | |
| BLUE bluebird bio | Downgrades: Market Perform | $1,120 | $8.50 | +13,076.47% | 11 | Nov 5, 2020 | |
| GILD Gilead Sciences | Maintains: Market Perform | $74 → $64 | $92.57 | -30.86% | 2 | Oct 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $14 | $42.25 | -66.86% | 1 | Jun 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $47 → $60 | $2.59 | +2,216.60% | 2 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $120 → $164 | $1.59 | +10,239.62% | 5 | Mar 8, 2018 |
Replimune Group
Mar 18, 2022
Maintains: Outperform
Price Target: $51 → $30
Current: $12.49
Upside: +140.19%
Jasper Therapeutics
Oct 20, 2021
Initiates: Outperform
Price Target: $190
Current: $21.57
Upside: +780.85%
Apellis Pharmaceuticals
Sep 10, 2021
Maintains: Outperform
Price Target: $89 → $69
Current: $33.21
Upside: +107.77%
Kodiak Sciences
May 11, 2021
Maintains: Market Perform
Price Target: $138 → $104
Current: $8.65
Upside: +1,102.31%
C4 Therapeutics
Mar 31, 2021
Initiates: Outperform
Price Target: $55
Current: $3.95
Upside: +1,292.41%
Arvinas
Mar 31, 2021
Initiates: Outperform
Price Target: $101
Current: $18.48
Upside: +446.54%
Regeneron Pharmaceuticals
Jan 25, 2021
Upgrades: Outperform
Price Target: $630
Current: $701.85
Upside: -10.24%
Madrigal Pharmaceuticals
Nov 6, 2020
Maintains: Market Perform
Price Target: $119 → $124
Current: $308.44
Upside: -59.80%
bluebird bio
Nov 5, 2020
Downgrades: Market Perform
Price Target: $1,120
Current: $8.50
Upside: +13,076.47%
Gilead Sciences
Oct 29, 2020
Maintains: Market Perform
Price Target: $74 → $64
Current: $92.57
Upside: -30.86%
Jun 5, 2020
Initiates: Outperform
Price Target: $14
Current: $42.25
Upside: -66.86%
Dec 3, 2019
Downgrades: Market Perform
Price Target: $47 → $60
Current: $2.59
Upside: +2,216.60%
Mar 8, 2018
Maintains: Market Perform
Price Target: $120 → $164
Current: $1.59
Upside: +10,239.62%